Icahn School of Medicine at Mount Sinai
Rajwanth Veluswamy, MD MSCR is an assistant professor of Medicine, Hematology and Medical Oncology, and a board-certified medical oncologist at the Icahn School of Medicine at Mount Sinai, who specializes in the treatment of lung cancer and other thoracic malignancies. He completed both a clinical and research fellowship in Hematology and Medical Oncology also at Mount Sinai. Dr. Veluswamy is a clinical and translational researcher focused on developing novel targeted and immunotherapy trials aimed at improving treatment outcomes in lung cancer patients. He leads a research program focused on KRAS mutated lung cancers at Mount Sinai and is PI of investigator-initiated trials studying novel combinations for this important subgroup. Dr. Veluswamy research also utilizes advances statistical approaches to improve our understanding of lung cancer biology and treatment outcomes, currently as a member of Mount Sinai’s Protoeogenomic Data Analysis Center (PGDAC) and in other collaborations leveraging natural language processing (NLP)-derived clinical data to develop treatment-related outcome classifiers. He has also published extensively on the comparative effectiveness of various lung cancer treatments. He is the recipient of an ASCO Young Investigator Award (2016), CTSA KL2 Scholars Award (2017), LCRF Award (2019), Dr. Harold and Golden Lamport Research Award (2022) and two SU2C grants (2022).
AstraZeneca (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board, Grant/Research Support, Grant/Research Support, Speaker's Bureau, Speaker's Bureau; BeiGene Ltd. (Individual(s) Involved: Self): Consultant, Consultant; BergenBio (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board; Boerhinger Ingelheim (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; Bristol-Meyers-Squibb (Individual(s) Involved: Self): Grant/Research Support, Grant/Research Support; OncoNova (Individual(s) Involved: Self; Clinical Condition: Oncology): Grant/Research Support, Grant/Research Support; Regeneron (Individual(s) Involved: Self; Clinical Condition: Oncology): Advisory Board, Advisory Board
Friday, October 14, 2022
10:40 AM – 11:45 AM
Friday, October 14, 2022
11:10 AM – 11:25 AM
Friday, October 14, 2022
11:25 AM – 11:45 AM
Wednesday, November 9, 2022
12:05 PM – 1:15 PM
Wednesday, November 9, 2022
12:30 PM – 12:50 PM
Wednesday, November 9, 2022
12:50 PM – 1:15 PM
Thursday, November 10, 2022
12:40 PM – 2:10 PM
Thursday, November 10, 2022
1:25 PM – 1:45 PM
Thursday, November 10, 2022
1:45 PM – 2:10 PM